TORONTO, Nov. 9 /CNW/ - The following B-Roll is available at the listed
times and co-ordinates:Live Satellite Coordinates:
DATE OF FEED No. 1: November 9, 2008
TIME OF FEED: 1:30 - 2:00 pm EST
CO-ORDINATES: Anik F2 C
Transponder 7B
Audio subcarrier 6.2 and 6.8
Downlink frequency 3980 vertical
DATE OF FEED No. 2: November 10, 2008
TIME OF FEED: 10:30 - 11:00 am EST
CO-ORDINATES: Anik F2 C
Transponder 7B
Audio subcarrier 6.2 and 6.8
Downlink frequency 3980 vertical
Broadcast on Demand URL:
DATE: November 9, 2008
TIME: 1:00 pm EST
http://cnw.pathfireondemand.com/viewpackage.action?packageid=112Please contact broadcast@newswire.ca to gain immediate access.
CNW's On-Demand service provides broadcast quality footage to accredited
journalists worldwide.
STORY SUMMARY:
Results of the JUPITER study were released today at the American Heart
Association and suggest that seemingly healthy Canadians may be saved from
first heart attacks, strokes, or even death if they are screened for elevated
hsC-reactive protein (hsCRP) and successfully lower their cholesterol levels,
even when their cholesterol levels are considered normal.
Nearly one half of all cardiovascular events occur in patients who are
apparently healthy and who have low or normal levels of low density
lipoprotein cholesterol (LDL-C), a traditional indicator of cardiovascular
risk.SHOT LIST:
Interview with Dr. Jacques Genest, McGill University Health Centre,
Montreal
Various b-roll:
- people exercising
- people eating
- Crestor product shots
Approx TRT: 1:30
Visual Audio
-------------------------------------------------------------------------
b-roll VO
Healthy people on streets Results released today at the American
Heart Association suggest that seemingly
Dr. b-roll healthy Canadians may be saved from
heart attacks, strokes, or even death if
they are screened for elevated
hsC-reactive protein (hsCRP) and
successfully lower their cholesterol
levels, even when their cholesterol
levels are considered normal.(1)
Dr. Jacque Genest, in Montreal explains.
-------------------------------------------------------------------------
Dr. Jacques Genest on cam Dr. Genest clip:
C-reactive protein belongs to a class of
molecules that are elevated in acute
inflammation. A low level of CRP but
elevated compared to normal, may reflect
chronic inflammation. And that may be
the only risk factor in patients who
have a normal LDL cholesterol and few
other cardiovascular risk factors.
-------------------------------------------------------------------------
b-roll of healthy people VO
Nearly one half of all cardiovascular
events occur in people who are
apparently healthy.(2)
-------------------------------------------------------------------------
Product shot VO
And/or insert: The trial showed that patients who
Text over a moving background received 20mg of CRESTOR(R) daily,
of key findings, stats, graph, (rosuvastatin calcium) had reduced
chart, etc. first cardiovascular events by 44%
compared to a placebo.(3) This is the
greatest reduction in risk seen in the
large placebo-controlled statin
trial.(4)
-------------------------------------------------------------------------
Dr. on cam Dr. Genest clip:
We've known for many years that more
than half of the patients who develop a
myocardial infarction have normal levels
of LDL cholesterol. It's also been known
for a while that C-reactive protein is
elevated in most patients with heart
disease and therefore, JUPITER tested
the hypothesis that treating normal LDL
cholesterol level but high CRP would
have a reduction in cardiovascular end
points.
-------------------------------------------------------------------------
STATIONS, FOR FURTHER INFORMATION, PLEASE CALL: Marlo Taylor
Fleishman-Hillard Canada Inc., 416-645-3652 office, 416-357-8540 mobile
marlo.taylor@fleishman.ca
For technical information DURING the satellite feed, please call CNW at
(416) 863-5615
Please contact broadcast@newswire.ca to get immediate access.
As with all CNW Broadcast feeds, this release is offered for your free
and unrestricted news use. Comments regarding the content and quality are
welcomed.
--------------------------------
(1) Ridker PM. Justification for the Use of Statins in Primary
Prevention: an Intervention Trial Evaluating Rosuvastatin.
Presentation at 2008 American Heart Association conference, New
Orleans
(2) Ridker PM, Rifai N, Clearfield M, Downs J, Weis SE, Miles JS, Gotto
A. Measurement of C-reactive Protein for the Targeting of Statin
Therapy in the Primary Prevention of Acute Coronary Events. N Engl J
Med 2001;344:1959-1965.
(3) Ridker PM. Justification for the Use of Statins in Primary
Prevention: an Intervention Trial Evaluating Rosuvastatin.
Presentation at 2008 American Heart Association conference, New
Orleans
(4) Ridker P, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent
vascular events in men and women with elevated C-reactive protein. N
Engl J Med 2008;359:2195-207
For further information: CNW BROADCAST, TORONTO, (416) 863-9350
